|
| 37421603 | Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma. | | 2023 |
| 36093992 | Primary gastric leiomyosarcoma presenting as a giant polyp. | Revista Espanola de Enfermedades Digestivas | 2023 |
| 36413412 | Sarcopenia identified by computed tomography imaging using a deep learning-based segmentation approach impacts survival in patients with newly diagnosed multiple myeloma. | Cancer | 2023 |
| 37603349 | Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy. | | 2023 |
| 37658775 | Superior detection rate of plasma cell FISH using FACS-FISH. | | 2023 |
| 36588384 | Survival trends in young patients with Waldenström macroglobulinemia: Over five decades of experience. | | 2023 |
| 37334773 | A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL). | | 2023 |
| 37019896 | Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma. | Blood Cancer J | 2023 |
| 37397374 | Therapy of childhood acute lymphoblastic leukemia in resource-poor geospaces. | | 2023 |
| 36878906 | Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients. | | 2023 |
| 36631454 | Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma. | | 2023 |
| 37003846 | Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma. | Clin Lymphoma Myeloma Leuk | 2023 |
| 37061416 | Impact of Disease Progression, Line of Therapy, and Response on Health-Related Quality of Life in Multiple Myeloma: A Systematic Literature Review. | | 2023 |
| 37439357 | Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study. | Haematologica | 2023 |
| 37230980 | Correction: Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients. | | 2023 |
| 36603945 | Almost a Centenarian-Bold, Forward, and Networking. | | 2023 |
| 37494698 | Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas. | | 2023 |
| 37494698 | Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas. | | 2023 |
| 34635783 | Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma. | Leukemia | 2022 |
| 36166729 | Assessing Patient-Reported Financial Hardship in Patients With Cancer in Routine Clinical Care. | JCO Oncology Practice | 2022 |
| 35940527 | Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy. | Transplantation and Cellular Therapy | 2022 |
| 35876190 | Insurance-based disparities impact survival outcomes in Waldenström macroglobulinemia within the United States. | Leukemia and Lymphoma | 2022 |
| 35800433 | Hypovitaminosis D Is Prevalent in Patients With Renal AL Amyloidosis and Associated With Renal Outcome. | Frontiers in Endocrinology | 2022 |
| 35549799 | Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation. | Leukemia and Lymphoma | 2022 |
| 36424376 | Second symptomatic COVID-19 infections in patients with an underlying monoclonal gammopathy. | Blood Cancer Journal | 2022 |
| 36444223 | Raise the Flag: Is Low QRS Voltage Ready to Advance to a Prognostic Factor? | JACC: CardioOncology | 2022 |
| 36473843 | Second- and third-line treatment strategies in multiple myeloma: a referral-center experience. | Blood Cancer Journal | 2022 |
| 36526617 | Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy. | | 2022 |
| 35297404 | Impact of maintenance therapy post autologous stem cell transplantation for multiple myeloma in early and delayed transplant. | Bone Marrow Transplantation | 2022 |
| 35235951 | Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma. | Blood advances | 2022 |
| 34978743 | Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome. | American Journal of Hematology | 2022 |
| 35190659 | Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio â¿¥100. | Leukemia | 2022 |
| 35175355 | Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma. | Blood Adv | 2022 |
| 35015310 | Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation. | American Journal of Hematology | 2022 |
| 34764424 | Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis. | Leukemia | 2022 |
| 34710241 | Prognostic significance of acquired 1q22 gain in multiple myeloma. | American Journal of Hematology | 2022 |
| 34822201 | Measles, rubella, and mumps titers post chemotherapy plus autologous stem cell transplant in multiple myeloma patients. | Am J Hematol | 2022 |
| 34822175 | Characteristics and risk factors for thrombosis in POEMS syndrome: A retrospective evaluation of 230 patients. | American Journal of Hematology | 2022 |
| 34702976 | Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. | Leukemia | 2022 |
| 35091659 | Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab. | Leukemia | 2022 |
| 35073929 | Double aneuploidy mosaicism involving chromosomes 18 and 21 in a neonate. | Molecular Cytogenetics | 2022 |
| 35102148 | A simple additive staging system for newly diagnosed multiple myeloma. | Blood Cancer Journal | 2022 |
| 34836942 | Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. | Blood Cancer Journal | 2021 |
| 34242392 | Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma. | Blood advances | 2021 |
| 33909933 | Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia. | American Journal of Hematology | 2021 |
| 34115387 | Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials. | American Journal of Hematology | 2021 |
| 33785296 | The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. | Clinical Lymphoma, Myeloma and Leukemia | 2021 |
| 33941766 | Economic burden of disease progression among multiple myeloma patients who have received transplant and at least one line of therapy in the US. | Blood Cancer Journal | 2021 |
| 33836869 | Prognostic Implications of Rising Serum Monoclonal Protein and Free Light Chains after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. | Transplantation and Cellular Therapy | 2021 |
| 34099625 | Correction: MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. | Blood Cancer J | 2021 |